Physician profile
Eric D Mann
NPI 1184040404
$5,033.78
in general payments reported to CMS, 2019-2025
24 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,846 · 2023: $2,767 · 2024: $302 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,187.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,033.42 | 2022-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $604.32 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Abbvie INC. | $575.07 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $360.94 | 2022-2024 | Ingrezza |
| Lundbeck LLC | $333.27 | 2022-2023 | Brintellix, Rexulti |
| Corium, LLC | $297.54 | 2022-2023 | Azstarys |
| Validus Pharmaceuticals LLC | $291.44 | 2022-2023 | Equetro |
| Janssen Pharmaceuticals, INC | $217.65 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $179.42 | 2023 | Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $153.19 | 2022 | |
| Almatica Pharma LLC | $144.03 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Noven Therapeutics, LLC | $132.90 | 2023 | Secuado |
| Takeda Pharmaceuticals U.S.A., INC. | $105.14 | 2022-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $100.26 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $91.02 | 2022-2023 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $75.65 | 2022-2025 | Fanapt |
| Harmony Biosciences LLC | $73.78 | 2022-2023 | Wakix |
| Tris Pharma INC | $66.15 | 2022-2023 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $54.88 | 2022 | |
| Bausch Health US, LLC | $54.07 | 2022-2023 | Wellbutrin, Aplenzin |
| Alkermes, INC. | $51.91 | 2023 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $14.24 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $14.02 | 2023 | Qelbree |
| Reprise Biomedical, INC. | $9.47 | 2025 | Miro 3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.